Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Zenas BioPharma Q3 2026 net loss more than doubles year over year to $108.9 million

By Public Technologies
  • Zenas BioPharma’s third-quarter 2026 net loss more than doubled year over year to $108.9 million.
  • Revenue rose to $10 million from no revenue a year earlier, attributable to a Bristol Myers Squibb development milestone.
  • Research and development expenses climbed 70% year over year to $58.5 million, primarily due to higher clinical, regulatory and personnel costs.
  • Cash, cash equivalents and investments totaled $647.1 million at September 30, 2026.
  • The FDA’s target action date for obexelimab in IgG4-related disease is May 27, 2027; the European marketing application was validated.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050700PRIMZONEFULLFEED9870813) on November 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.